Overview

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Status:
Not yet recruiting

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)

Phase:

Phase 2

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Treatments:

Antibodies, Monoclonal
Carboplatin
Cisplatin
Durvalumab
Pemetrexed